Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$2.21 ▼ -0.07
(-3.07%)
MKT CAP: $32.3M • VOL: 26.8K
52W L $2 52W H $8
QTI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $18.9M | $4.9M | $40.4K |
| YoY Revenue Growth % | +287.9% | +11990.2% | — |
| Gross Profit | $8.6M | $2.6M | — |
| Gross Margin % | 45.4% | 54.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$4.4M | -$12.2M | -$5.0M |
| Operating Margin % | -23.4% | -80.0% | -80.0% |
| Net Income (GAAP) | -$21.1M | -$9.0M | -$6.1M |
| EBITDA (Normalized) | -$4.3M | -$12.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$9.0M | -$10.0M | -$2.7M |
| Capital Expenditures (CapEx) | $124.0K | $88.0K | — |
| Free Cash Flow (FCF) | -$9.1M | -$10.1M | -$2.7M |
| FCF Margin % | -48.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $10.4M | $1.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $6.4M | -$9.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR QTI.